Prenatal Enzyme-Replacement Therapy

被引：2
|
作者：
van der Ploeg, Ans T. [1 ]
机构：
[1] Erasmus MC Univ Med Ctr, Ctr Lysosomal & Metab Dis, Dept Pediat, Rotterdam, Netherlands
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2022年 / 387卷 / 23期
关键词：
D O I：
10.1056/NEJMe2211515
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Enzyme-Replacement Therapy - A Primer This article explains the genetic basis of Pompe's disease and other lysosomal storage disorders, as well as the foundations of enzyme-replacement therapy.
引用
收藏
页码：2189 / 2193
页数：5
相关论文
共 50 条
  • [31] Plasma lipoprotein responses to enzyme-replacement in Gaucher's disease
    Cenarro, A
    Pocovi, M
    Giraldo, P
    Garcia-Otin, AL
    Ordovas, JM
    LANCET, 1999, 353 (9153): : 642 - 643
  • [32] CRIM status and antibody formation in patients with classic infantile Pompe disease treated with enzyme-replacement therapy
    van Gelder, C. M.
    Kroos, M. A.
    Ozkan, L.
    van der Ploeg, A. T.
    Reuser, A. J.
    NEUROMUSCULAR DISORDERS, 2011, 21 (9-10) : 699 - 699
  • [33] Mucopolysaccharidosis: Cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI
    Brands, Marion M. M. G.
    Frohn-Mulder, Ingrid M.
    Hagemans, Marloes L. C.
    Hop, Wim C. J.
    Oussoren, Esmee
    Helbing, Wim A.
    van der Ploeg, Ans T.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2013, 36 (02) : 227 - 234
  • [34] Enzyme-Replacement Therapy in Life-Threatening Hypophosphatasia: The 3-Year Experience with Asfotase Alfa.
    Whyte, Michael
    Simmons, Jill H.
    Lutz, Richard E.
    Moseley, Scott
    Melian, Agustin
    Odrljin, Tatjana
    Bishop, Nicholas
    JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 : S120 - S120
  • [35] Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice
    Gliddon, BL
    Hopwood, JJ
    PEDIATRIC RESEARCH, 2004, 56 (01) : 65 - 72
  • [36] Enzyme-Replacement Therapy from Birth Delays the Development of Behavior and Learning Problems in Mucopolysaccharidosis Type IIIA Mice
    Briony L Gliddon
    John J Hopwood
    Pediatric Research, 2004, 56 : 65 - 72
  • [37] Basilar Artery Diameter is Associated With Cerebral Small Vessel Disease and the Duration of Enzyme-replacement Therapy in Fabry Disease
    Miwa, Kaori
    Sakai, Norio
    Yagita, Yoshiki
    Takeuchi, Mariko
    Todo, Kenichi
    Sakaguchi, Manabu
    Mochizuki, Hideki
    STROKE, 2018, 49
  • [38] 18-year follow-up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I
    Pjetraj, Dorina
    Santoro, Lucia
    Sgattoni, Claudia
    Padella, Lucia
    Zampini, Lucia
    Monachesi, Chiara
    Gabrielli, Orazio
    Catassi, Carlo
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2023, 191 (02) : 564 - 569
  • [39] CRIM STATUS, ANTIBODY FORMATION AND NEUTRALIZING ANTIBODIES IN PATIENTS WITH CLASSIC INFANTILE POMPE DISEASE TREATED WITH ENZYME-REPLACEMENT THERAPY
    van Gelder, C. M.
    Kroos, M. A.
    Ozkan, L.
    van der Ploeg, A. T.
    Reuser, A. J. J.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2011, 34 : S226 - S226
  • [40] Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I
    Kakavanos, R
    Turner, CT
    Hopwood, JJ
    Kakkis, ED
    Brooks, DA
    LANCET, 2003, 361 (9369): : 1608 - 1613
12345